[144] Alignment Healthcare, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Alignment Healthcare, Inc. (ALHC) reports a proposed sale of 35,000 shares of common stock through E-Trade with an aggregate market value of $555,100, and an approximate sale date of 09/08/2025. The filing lists 198,031,417 shares outstanding. The securities to be sold were originally acquired as a stock award on 09/06/2023 under the issuer's 2021 Equity Incentive Plan, showing 61,256 shares acquired on that date. The filing also discloses prior sales under a 10b5-1 plan: 15,491 shares sold on 07/31/2025 for gross proceeds of $247,950.50. Other filer contact and CIK details are not provided in the document content.

Positive

• Discloses planned sale details including number of shares, market value, sale date, and broker
• Source of shares identified as a stock award under the 2021 Equity Incentive Plan (09/06/2023)
• Shows prior 10b5-1 activity (15,491 shares sold on 07/31/2025 for $247,950.50), increasing transparency

Negative

• Administrative fields incomplete or blank in the provided content (e.g., filer CIK and contact details not shown)
• Filing does not include additional contextual disclosures beyond basic sale and acquisition data

Insights

Securities Analyst

TL;DR: Insider plans to sell a modest block of shares from a prior award; prior 10b5-1 activity is disclosed, suggesting rule-compliant execution.

The proposed sale of 35,000 shares (aggregate value $555,100) appears to be a routine disposition from equity awards granted on 09/06/2023 under the 2021 Equity Incentive Plan. The disclosure of a 10b5-1 sales plan and a recent sale of 15,491 shares on 07/31/2025 (gross proceeds $247,950.50) provides useful transparency on recent insider liquidity. Given the outstanding share count of 198,031,417, the size of the proposed sale is small relative to the company’s float, implying limited market impact. The filing lacks fuller filer contact and CIK details which would normally aid investor verification.

Corporate Governance Expert

TL;DR: Disclosure follows Rule 144 format and references a 10b5-1 plan; documentation is consistent with standard insider selling practices.

The notice identifies the source of the shares as a stock award and confirms a separate 10b5-1 sale earlier in the quarter, which collectively indicate planned, rule-compliant liquidity rather than opportunistic trading. The filing includes required representations about absence of undisclosed material information. Missing administrative fields (e.g., filer CIK) are present as blanks in the provided content, which limits administrative traceability but does not change the substance of the sale disclosure.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	E-Trade Finance PO Box 101600 Arlington VA 22210-4600	35000	555100	198031417	09/08/2025	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/06/2023	The Common Stock was acquired through the grant of a stock award on 09/06/2023 under the Issuer's 2021 Equity Incentive Plan	Alignment Healthcare, Inc. (Issuer)			61256	09/06/2023	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales Plan for Christopher Joyce 1100 W. Town & Country Road, Suite 1600 Orange CA 92868	Common Stock	07/31/2025	15491	247950.50

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for ALHC report?

The form reports a proposed sale of 35,000 common shares through E-Trade with an aggregate market value of $555,100 and an approximate sale date of 09/08/2025.

How were the shares being sold acquired?

The shares were acquired as a stock award on 09/06/2023 under Alignment Healthcare's 2021 Equity Incentive Plan, totaling 61,256 shares acquired on that date.

Has the insider sold any ALHC shares recently?

Yes. The filing discloses a 10b5-1 sale of 15,491 shares on 07/31/2025 for gross proceeds of $247,950.50.

Who is the seller named in the document?

The 10b5-1 sales plan referenced is for Christopher Joyce as listed in the past-sales table in the filing content.

Does the filing indicate undisclosed material information?

By signing the notice the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed, as stated in the filing text.